Price Chart

Profile

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
URL https://www.equilliumbio.com
Investor Relations URL N/A
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 25, 2025 (est.)
Last Earnings Release Nov. 13, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
URL https://www.equilliumbio.com
Investor Relations URL N/A
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 25, 2025 (est.)
Last Earnings Release Nov. 13, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A